[1] [1] COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer［J］ . The Lancet, 2019, 393(10167): 169-182.

[2] [2] FERRALL L, LIN K Y, RODEN R B S, et al. Cervical cancer im-munotherapy: facts and hopes［J］ . Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2021, 27(18): 4953-4973.

[3] [3] POST C C B, WESTERMANN A M, BOSSE T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic en-dometrial cancer［J］ . Critical Reviews in Oncology/Hematology, 2020, 152: 102973.

[4] [4] SHIMOKAWA M, KOGAWA T, SHIMADA T, et al. Overall sur-vival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recur-rent epithelial ovarian cancer［J］ . Journal of Cancer, 2018, 9(5): 872-879.

[5] [5] TEWARI K S, SILL M W, PENSON R T, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gy-necologic Oncology Group 240)［J］ . Lancet (London, England), 2017, 390(10103): 1654-1663.

[7] [7] TOPALIAN S L, TAUBE J M, PARDOLL D M. Neoadjuvant checkpoint blockade for cancer immunotherapy［J］ . Science (New York, NY), 2020, 367(6477): eaax0182.

[8] [8] CHUNG H C, ROS W, DELORD J P, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study［J］ . Journal of Clinical Oncology, 2019, 37(17): 1470-1478.

[9] [9] NAUMANN R W, HOLLEBECQUE A, MEYER T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkmate 358 trial［J］ . Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2019, 37(31): 2825-2834.

[10] [10] TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins［J］ . Science (New York, NY), 2022, 375(6586): 1254-1261.

[11] [11] JIANG X, STOCKWELL B R, CONRAD M. Ferroptosis: mecha-nisms, biology and role in disease［J］ . Nature Reviews Molecular Cell Biology, 2021, 22(4): 266-282.

[12] [12] KAHLSON M A, DIXON S J. Copper-induced cell death［J］ . Sci-ence (New York, NY), 2022, 375(6586): 1231-1232.

[14] [14] ATAKUL T, OZLEM A S, ABAS BURCIN I, et al. Serum copper and zinc levels in patients with endometrial cancer［J］ . Biological Trace Element Research, 2020, 195(1): 46-54.

[15] [15] FENG Y, ZENG J W, MA Q, et al. Serum copper and zinc levels in breast cancer: a meta-analysis［J］ . Journal of Trace Elements in Medicine and Biology, 2020, 62: 126629.

[16] [16] PAVITHRA V, SATHISHA T G, KASTURI K, et al. Serum levels of metal ions in female patients with breast cancer［J］ . Journal of Clinical and Diagnostic Research, 2015, 9(1): BC25-BC27.

[17] [17] ZHANG M, SHI M, ZHAO Y. Association between serum copper levels and cervical cancer risk: a meta-analysis［J］ . Bioscience Reports, 2018, 38(4): BSR20180161.

[18] [18] CHEN B, ZHOU X, YANG L, et al. A cuproptosis activation scor-ing model predicts neoplasm-immunity interactions and personal-ized treatments in glioma［J］ . Computers in Biology and Medi-cine, 2022, 148: 105924.

[21] [21] SIMON N, FRIEDMAN J, HASTIE T, et al. Regularization paths for cox’s proportional hazards model via coordinate descent［J］ . Journal of Statistical Software, 2011, 39(5): 1-13.

[22] [22] JIANG P, GU S, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response［J］ . Nature Medicine, 2018, 24(10): 1550-1558.

[23] [23] LI Y, CHEN Z, TAO W, et al. Tumor mutation score is more pow-erful than tumor mutation burden in predicting response to immu-notherapy in non-small cell lung cancer［J］ . Cancer Immunology, Immunotherapy, 2021, 70(8): 2367-2378.

[24] [24] SHA D, JIN Z, BUDCZIES J, et al. Tumor mutational burden as a predictive biomarker in solid tumors［J］ . Cancer Discovery, 2020, 10(12): 1808-1825.

[25] [25] GEELEHER P, COX N, HUANG R S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels［J］ . PLoS One, 2014, 9(9): e107468.

[26] [26] READY N, HELLMANN M D, AWAD M M, et al. First-line niv-olumab plus ipilimumab in advanced non-small-cell lung cancer (checkmate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］ . Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2019, 37(12): 992-1000.

[27] [27] ZHOU F, DONG C, DAVIS J E, et al. The mechanism and func-tion of mitogen-activated protein kinase activation by ARF1［J］ . Cellular Signalling, 2015, 27(10): 2035-2044.

[28] [28] ZHANG Z, MA Y, GUO X, et al. FDX1 can impact the prognosis and mediate the metabolism of lung adenocarcinoma［J］ . Front Pharmacol, 2021, 12: 749134.

[29] [29] XIAO C, YANG L, JIN L, et al. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer［J］ . Fron-tiers in Genetics, 2022, 13: 962028.

[30] [30] TAKAGI K, ITO S, MIYAZAKI T, et al. Amyloid precursor protein in human breast cancer: an androgen-induced gene associ-ated with cell proliferation［J］ . Cancer Science, 2013, 104(11): 1532-1538.

[31] [31] LIM S, YOO B K, KIM H S, et al. Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer［J］ . BMC Cancer, 2014, 14: 928.

[32] [32] SHI X, DENG Z, WANG S, et al. Increased HSF1 promotes in-filtration and metastasis in cervical cancer via enhancing MTDH-VEGF-C expression［J］ . Oncotargets and Therapy, 2021, 14: 1305-1315.

[33] [33] HURLEY E H, TAO J, LIU S, et al. Inhibition of heat shock fac-tor 1 signaling decreases hepatoblastoma growth via induction of apoptosis［J］ . American Journal of Pathology, 2023, 193(2): 148-160.

[34] [34] CASCIARO B, MANGIARDI L, CAPPIELLO F, et al. Naturally-occurring alkaloids of plant origin as potential antimicrobials against antibiotic-resistant infections［J］ . Molecules, 2020, 25(16): 3619.

[35] [35] YU X, XU Q, CHENW, et al. Rhein inhibits Chlamydia tracho-matis infection by regulating pathogen-host cell［J］ . Frontiers in Public Health, 2022, 10: 1002029.